N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine | 131760-67-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine
• 英文别名: 2-Mercapto-N'-(2-mercaptoacetyl)-N,N'-dimethylacetohydrazide；N,N'-dimethyl-2-sulfanyl-N'-(2-sulfanylacetyl)acetohydrazide
• CAS: 131760-67-3
• 化学式: C₆H₁₂N₂O₂S₂
• 分子量: 208.305
• InChiKey: CQAWAFDKTQPIHN-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38 °C
• 沸点：
  288.4±50.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  42.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine 在 乙二胺四乙酸 、 (4S,5S)-1,2-二噻烷-4,5-二醇 作用下， 以 aq. phosphate buffer 为溶剂， 反应 24.0h， 生成 1,2-dimethyl-3,8-dioxo-1,2,5,6-diazadithiocane
  参考文献：
  名称：

  Pyrazine-derived disulfide-reducing agent for chemical biology

  摘要：

  在过去五十年中，二硫苏糖醇（DTT）一直是还原蛋白质和其他生物分子中二硫键的首选试剂。本文报道了2,3-双（巯基甲基）吡嗪（BMMP）的合成与表征，这是一种易于获得的二硫还原剂，其在生物条件下的反应性显著优于DTT及其他已知试剂。

  DOI：

  10.1039/c4cc04491f
• 作为产物：
  描述：

  N,N'-dimethyl-N,N'-bis(chloroacetyl)hydrazine 在 盐酸 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 80.5h， 生成 N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine
  参考文献：
  名称：

  A reagent for reduction of disulfide bonds in proteins that reduces disulfide bonds faster than does dithiothreitol

  摘要：

  We have synthesized a new reagent--N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine (DMH)-for the reduction of disulfide bonds in proteins. DMH reduces disulfid bonds 7 times faster than does dithiothreitol (DTT) in water at pH 7. DMH reduces mixed disulfides of cysteine proteases (papain and ficin) especially rapdily (30 times faster than DTT). DMH (epsilon-degrees = -0.300 V) reduces noncyclic disulfides completely, although it is less strongly reducing than DTT (epsilon-degrees = -0.356 V).

  DOI：

  10.1021/jo00007a018

文献信息

• [EN] TWO-WAY MAGNETIC RESONANCE TUNING NANOPROBE ENHANCED SUBTRACTION IMAGING<br/>[FR] IMAGERIE À SOUSTRACTION AMÉLIORÉE PAR NANOSONDE À ACCORD DE RÉSONANCE MAGNÉTIQUE BIDIRECTIONNELLE
  申请人：UNIV CALIFORNIA

  公开号：WO2021126989A1

  公开（公告）日：2021-06-24

  The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising: a plurality of amphiphilic compounds that self-assemble to form the nanocarrier; and a first magnetic resonance imaging (MRI) contrast agent and a second MRI contrast agent in the interior; wherein one MRI contrast agent is paramagnetic, and the other MRI contrast agent is superparamagnetic, and the first MRI contrast agent and the second MRI contrast agent are configured within the interior to substantially cancel the magnetic signal of each contrast agent. The present invention also provides a method of using the nanocarriers for imaging and detecting a disease, as well as novel telodendrimer compounds.

  本发明提供了一种具有内部和外部结构的纳米载体，该纳米载体包括：多种两亲性化合物，它们自我组装形成纳米载体；以及一种第一磁共振成像（MRI）对比剂和一种第二MRI对比剂位于内部；其中一种MRI对比剂是顺磁性的，另一种MRI对比剂是超顺磁性的，第一MRI对比剂和第二MRI对比剂在内部结构中配置，以基本上相互抵消各自的磁信号。本发明还提供了使用这些纳米载体进行成像和检测疾病的方法，以及新颖的支线状聚合物化合物。
• Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB)
  申请人：——

  公开号：US20020052344A1

  公开（公告）日：2002-05-02

  The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. 1 The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明包括一类新颖的化合物，这些化合物由公式I表示，是PTP-1B酶的抑制剂。 本发明还包括用于治疗或预防PTP-1B介导的疾病的药物组合物和方法，包括糖尿病、肥胖症和与糖尿病相关的疾病。
• Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
  申请人：——

  公开号：US20020002149A1

  公开（公告）日：2002-01-03

  The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. 1 The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.

  本发明包括一类新颖的化合物，其通过以下公式表示，这些化合物是PTP-1B酶的抑制剂。 1 本发明还包括用于治疗或预防PTP-1B介导的疾病的药物组合物和方法，包括糖尿病。
• Cosmetic composition based on a cosmetically active compound and a gel comprising at least one crosslinked network of crosslinked polymer particles
  申请人：Mathonneau Estelle

  公开号：US20050186165A1

  公开（公告）日：2005-08-25

  The present disclosure relates to a cosmetic composition, especially a hair composition, comprising, in a cosmetically acceptable medium, at least one cosmetically active compound and a gel comprising at least one crosslinked network of crosslinked polymer particles. The disclosure is also directed towards a method for fixing and/or holding a hairstyle using the composition, and also to the method of manufacturing a gel cosmetic formulation for holding and/or fixing the hairstyle.

  本公开涉及一种化妆品组合物，特别是一种头发组合物，包括至少一种化妆上可接受的介质中的至少一种化妆活性化合物和一种明胶，该明胶包括至少一种交联聚合物粒子的交联网络。该公开还涉及一种使用该组合物固定和/或保持发型的方法，以及制备用于保持和/或固定发型的明胶化妆配方的方法。
• NUCLEOTIDE ANALOGUES
  申请人：Intelligent Biosystems, Inc.

  公开号：US20170130051A1

  公开（公告）日：2017-05-11

  The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3′-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.

  本发明提供了利用包含由甲亚砜二硫醚作为可裂解保护基团的3'-O位置封端的脱氧核苷三磷酸的方法、组合物、混合物和试剂盒，以及可逆地连接到所述脱氧核苷的核碱基的可检测标签。这些化合物为未来的测序技术提供了新的可能性，包括但不限于合成测序。